Dupilumab is the first FDA-approved biologic for the treatment of atopic dermatitis; it is indicated for the treatment of moderate-to-severe atopic dermatitis (eczema) in patients aged 12 years and older, providing rapid and sustained improvement in skin lesions and pruritus.